Your browser doesn't support javascript.
loading
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience.
Gisondi, Paolo; Piaserico, Stefano; Naldi, Luigi; Dapavo, Paolo; Conti, Andrea; Malagoli, Piergiorgio; Marzano, Angelo Valerio; Bardazzi, Federico; Gasperini, Massimo; Cazzaniga, Simone; Costanzo, Antonio.
Afiliación
  • Gisondi P; Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy. Electronic address: paolo.gisondi@univr.it.
  • Piaserico S; Department of Medicine, Section of Dermatology, University of Padua, Padua, Italy.
  • Naldi L; Centro Studi GISED, Bergamo, Italy; Department of Dermatology, San Bortolo Hospital, Vicenza, Italy.
  • Dapavo P; Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy.
  • Conti A; Department of Surgical, Medical, Dental and Morphological Sciences related to Transplant, Oncology and Regenerative Medicine, Dermatology Unit, University of Modena and Reggio Emilia, Modena, Italy.
  • Malagoli P; Azienda Ospedaliera San Donato Milanese, Dermatology Unit, Milan, Italy.
  • Marzano AV; Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
  • Bardazzi F; Dermatology Unit, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
  • Gasperini M; Ospedale Guglielmo da Saliceto, Dermatology Unit, Piacenza, Italy.
  • Cazzaniga S; Centro Studi GISED, Bergamo, Italy; Department of Dermatology, San Bortolo Hospital, Vicenza, Italy; Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy; Department of Surgical, Medical, Dental and Morphological Sciences related to Trans
  • Costanzo A; Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy; Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.
J Allergy Clin Immunol ; 147(2): 558-560.e1, 2021 Feb.
Article en En | MEDLINE | ID: mdl-33160968
ABSTRACT

INTRODUCTION:

Whether biologic therapies enhance the risk of coronavirus 2019 (COVID-19) or affect the disease outcome in patients with chronic plaque psoriasis remains to be ascertained.

OBJECTIVE:

We sought to investigate the incidence of hospitalization and death for COVID-19 in a large sample of patients with plaque psoriasis receiving biologic therapies compared with the general population.

METHODS:

This is a retrospective multicenter cohort study including patients with chronic plaque psoriasis (n = 6501) being treated with biologic therapy and regularly followed up at the divisions of dermatology of several main hospitals in the Northern Italian cities of Verona, Padua, Vicenza, Modena, Bologna, Piacenza, Turin, and Milan. Incidence rates of hospitalization and death per 10,000 person-months with exact mid-p 95% CIs and standardized incidence ratios were estimated in the patients with psoriasis and compared with those in the general population in the same geographic areas.

RESULTS:

The incidence rate of hospitalization for COVID-19 was 11.7 (95% CI, 7.2-18.1) per 10,000 person-months in patients with psoriasis and 14.4 (95% CI, 14.3-14.5) in the general population; the incidence rate of death from COVID-19 was 1.3 (95% CI, 0.2-4.3) and 4.7 (95% CI, 4.6-4.7) in patients with psoriasis and the general population, respectively. The standardized incidence ratio of hospitalization and death in patients with psoriasis compared with those in the general population was 0.94 (95% CI, 0.57-1.45; P = .82) and 0.42 (95% CI, 0.07-1.38; P = .19), respectively.

CONCLUSIONS:

Our data did not show any adverse impact of biologics on COVID-19 outcome in patients with psoriasis. We would not advise biologic discontinuation in patients on treatment since more than 6 months and not infected with severe acute respiratory syndrome coronavirus 2 to prevent hospitalization and death from COVID-19.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Productos Biológicos / COVID-19 / Tratamiento Farmacológico de COVID-19 / Hospitalización Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Allergy Clin Immunol Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Productos Biológicos / COVID-19 / Tratamiento Farmacológico de COVID-19 / Hospitalización Tipo de estudio: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Allergy Clin Immunol Año: 2021 Tipo del documento: Article